These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3810518)

  • 21. The diagnosis of adverse medical events associated with drug treatment.
    Stephens MD
    Adverse Drug React Acute Poisoning Rev; 1987; 6(1):1-35. PubMed ID: 3303863
    [No Abstract]   [Full Text] [Related]  

  • 22. [How to assess the risk of drugs?].
    Roujeau JC
    Ann Dermatol Venereol; 1998 Oct; 125(10):673-5. PubMed ID: 9835953
    [No Abstract]   [Full Text] [Related]  

  • 23. [Microcomputerized data bank of nephrotoxic drugs at the Paris-Saint Antoine Regional Drug Monitoring Center].
    Hamel JD; Biour M; Cheymol G
    Therapie; 1986; 41(5):327-9. PubMed ID: 3810519
    [No Abstract]   [Full Text] [Related]  

  • 24. [Information centers on undesirable effects of drugs: also on alerting function].
    Bégaud B; Péré JC; Tubert P; Barat C; Haramburu F; Albin H
    Therapie; 1987; 42(2):231-7. PubMed ID: 3617000
    [No Abstract]   [Full Text] [Related]  

  • 25. [Advantages of a microcomputer system in researching duplicated reports].
    Biour M; Wagniart F; Jablonka J; Hamel JD; Weissenburger J; Cheymol G
    Therapie; 1986; 41(5):383-4. PubMed ID: 3810530
    [No Abstract]   [Full Text] [Related]  

  • 26. Revised ADR report permits internal review of drug experience.
    Jeffrey LP
    Pharm Times; 1986 Dec; 52(12):48-50. PubMed ID: 10317827
    [No Abstract]   [Full Text] [Related]  

  • 27. [Critical analysis of the adverse effects reported to the Paris-Fernand Widal Drug Monitoring Center in a 2-month period].
    Castot A; Carlier P; Lagier G; Elmalem J; Vincens M; Efthymiou M
    Therapie; 1986; 41(5):375-7. PubMed ID: 3810528
    [No Abstract]   [Full Text] [Related]  

  • 28. Postmarketing management of drug use: toward rational public policy.
    Spitzer WO; Hutchinson T; Lane D
    CMAJ; 1987 May; 136(10):1022-4. PubMed ID: 3567760
    [No Abstract]   [Full Text] [Related]  

  • 29. ["There are clear criteria for product surveillance studies"].
    Throm S
    MMW Fortschr Med; 2009 Aug; 151(34-35):7. PubMed ID: 19771777
    [No Abstract]   [Full Text] [Related]  

  • 30. [Physician and pharmaceutical industry. II. Postmarketing surveillance].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1992 Jan; 136(1):36-41. PubMed ID: 1728761
    [No Abstract]   [Full Text] [Related]  

  • 31. [Drug safety. Notes about surveillance].
    Moreno Alvarez PJ; Madurga Sanz M
    Farm Hosp; 2004; 28(3):225-8. PubMed ID: 15222877
    [No Abstract]   [Full Text] [Related]  

  • 32. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 33. Notifying patients of adverse drug reactions.
    Pane FJ; Ringer L; Ferguson L; Koshko N
    Am J Hosp Pharm; 1991 Feb; 48(2):236-7. PubMed ID: 2003491
    [No Abstract]   [Full Text] [Related]  

  • 34. Multicenter study of hospital adverse drug reactions.
    Conforti A; Leone R; Moretti U; Sartori M; Velo GP
    Acta Physiol Hung; 1990; 75 Suppl():63-4. PubMed ID: 2196759
    [No Abstract]   [Full Text] [Related]  

  • 35. Post marketing surveillance. Traps for the unwary.
    Marley J; Mant A
    Aust Fam Physician; 1993 Jun; 22(6):1009-11, 1013. PubMed ID: 8338446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of Canadian pharmacist involvement in adverse drug reaction reporting.
    Taras-Zasowski KM; Einarson TR
    Can J Hosp Pharm; 1989 Jun; 42(3):105-8, 133. PubMed ID: 10318271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cost/benefit analysis of a regional drug surveillance center].
    Mignot G; Chichmanian RM; Spreux A; Bernard G
    Therapie; 1988; 43(5):377-8. PubMed ID: 3147546
    [No Abstract]   [Full Text] [Related]  

  • 38. [Is establishment of causality in drug surveillance reliable?].
    Evreux JC
    Therapie; 1984; 39(4):437-8. PubMed ID: 6484888
    [No Abstract]   [Full Text] [Related]  

  • 39. [4-year experience in drug surveillance].
    Capellà D; Avila P; Cabeza L; Moreno V; Vidal X; Laporte JR
    Med Clin (Barc); 1988 Jun; 91(3):93-6. PubMed ID: 3172912
    [No Abstract]   [Full Text] [Related]  

  • 40. [Drug surveillance: the concept, the need and methods].
    Moreno González A
    An R Acad Nac Med (Madr); 1992; 109(1):197-218; discussion 218-20. PubMed ID: 1463138
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.